Araştırma Makalesi
PDF Mendeley EndNote BibTex Kaynak Göster

Seroprevalence of HBsAg, Anti-HBs, Anti-HCV and Anti-HIV in Behçet’s Disease

Yıl 2021, Cilt 11, Sayı 5, 690 - 693, 17.09.2021
https://doi.org/10.16899/jcm.912691

Öz

Introduction: Behçet's disease defined by Turkish dermatologist Hulusi Behçet is an inflammatory disease of unknown etiology and characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis and skin lesions. We aimed to evaluate hepatitis B virus, hepatitis C virus and human immunodeficiency virus seroprevalence in Behçet's Disease. Material and Method: Patients diagnosed with Behçet’s diseaseand followed up by the dermatology outpatient clinic during 12-years period between July 2008 and July 2020 were retrospectively analyzed. Demographic datas and HBsAg, anti-HBs, anti-HCV, Anti-HIV results of the patients were recorded. Results: 359 patients with Behçet’s disease were been evaluated in this study. Of these patients, 189 (52.6%) were female, 170 (47.4%) were male and the mean age was 37.7±12.3 years. HBsAg was positive in 6 (1.6%) patients and Anti-Hbs ab in 82 (7.7%) patients. Anti HIV ab was negative in all patients. Anti-HCV antibodies were found positive in only one case (0.2%), and this was confirmed by testing for hepatitis C virus-ribonucleic acid (HCV RNA). HCV RNA was negative in this patient. Conclusion: When compared with the general population, seropositivity rates were not detected to be high in Behçet's patients. In fact, the immunity rates were found very low. Based on such a finding, it was concluded that screening is required due to increasing immunosupressive treatments today, and individuals should be vaccinated in cases where HBV indicators are negative.In the other studies, investigating the entity, seropositivity rates have been found similar to those in the population. Considering that serological data show regional differences, we thought that, our study will contribute to the literature both national and international grades due to large patient population in our region.

Kaynakça

  • REFERENCES 1. Alibaz-Oner F, Direskeneli H. Behçet’s Disease: Clinical Features. In: Tüzün E. Kürtüncü M. (eds) Neuro-Behçet’s Disease. Springer, Cham 2021: 55-62.
  • 2. Sakane T, Mitsuhiro C, Suzuki N, Inaba G. Behçet's Disease. N Engl J Med 1999; 341: 1284-91.
  • 3. Idil A, Gürler A, Boyvat A, et al. The prevalence of Behçet’s disease above the age of 10 years. The results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. Ophthalmic Epidemiol. 2002; 9: 325–31.
  • 4. Alpsoy E, Donmez L, Onder M, et al. Clinical features and natural course of Behçet’s disease in 661 cases: a multicentre study. Br J Dermatol. 2007; 157: 901–6.
  • 5. Alpsoy E. Behçet’s disease: Treatment of mucocutaneous lesions. Clin Exp Rheumatol. 2005; 23: 532-9.
  • 6. EASL clinical practice guidelines. Management of chronic hepatitis B virusinfection. J Hepato 2017; l57: 167-85.
  • 7. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's diseas-An update Seminars in Arthritis and Rheumatism 2001; 30: 299-312.
  • 8. Law MF, Ho R, Cheung CK, Tam LHP, Ma K, So KCY et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol 2016; 22: 6484-500.
  • 9. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25: 864-71.
  • 10. Weinbaum CM, Williams I, Mast EE, Wang Sa, Finelli L, Wasley A et al. Recommendations for identification and public health management of persons with chronic hepatitis B virusinfection. MMWR Recomm Rep 2008; 57: 1-20
  • 11. Farajzadeh S, Shakibi MR, Darvish Moghaddam S, Rahnama Z. Behçet disease: clinical spectrum and association with hepatitis B and C viruses. Eastern Mediterranean Health J 2005; 11: 68-72.
  • 12. Etem AA, Etem EÖ, Doğan GT, Yıldırmak ST, Öz I. Seroprevalence of Hepatitis B, C Virus and HIV in Behçet’s Disease Living in Usak Region. J Clin Anal Med 2013; 4: 96-8.
  • 13. Munke H, Stockmann F, Ramadori G. Possible association between Behçet’s syndrome and chronic hepatitis C virus infection. New EngJ Med 1995; 332: 400–1.
  • 14. Hamuryudan V, Sonsuz A, Yurdakul S. More on hepatitis C virus and Behçet’s syndrome. New EngJ Med 1995; 333: 322–3.
  • 15. Ilter N, Şenol E, Gürer MA, Öztaş MO. Behçet’s disease and HCV infection. Int J Dermatol 2000; 39: 396–7.
  • 16. Vega LE, Espinoza LR. Vasculitides in HIV Infection. CurrRheumatolRep2020; 22: 60.
  • 17. Zhang X, Li H, Li T, Zhang F, Han Y. Distinctive rheumatic manifestations in 98 patients with human immunodeficiency virus infection in China. J Rheumatol 2007; 34: 1760–4.
  • 18. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011; 90: 359-71.
  • 19. Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.Gastroenterology 2017;152: 1297–309.
  • 20. Karadağ Ö, Kaşifoğlu T, Özer B, et al. Romatolojik hastalarda biyolojik ilaç kullanımı öncesi (viral) hepatit tarama kılavuzu. RAED Derg2015; 7: 28-32.
  • 21. Asan A, Akbulut A, Sacar S, Turgut H. Tunceli Devlet Hastanesi’ne başvuran kişilerde HBsAg ve Anti-HCV seroprevalansının değerlendirilmesi. Viral Hepatit Derg 2011; 17: 52-6.
  • 22. Tunç N, Eraydın H, Çetinkaya E, Oduncu MK, Toy Ş. Siirt Devlet Hastanesi’ne Başvuran Hastalarda HBsAg, Anti-HBs, Anti- HCV ve Anti-HIV Seroprevalansı. Viral Hepatit Derg. 2011; 17: 7-11.
  • 23. Demirpençe Ö, Tezcan SI, Değirmen E, Mert D, Gümüş A, Çelen MK. Batman Devlet Hastanesi’ne başvuran kişilerde Hepatit ve HIV Serolojisinin Sonuçları. Viral Hepatit Derg2012; 18: 6-10.
  • 24. İnci A, Okay M, Güven D. Artvin Devlet Hastanesi’ne Başvuran Hastalarda HBsAg, Anti-HBs, Anti-HCV ve Anti-HIV Seroprevalansı. Viral Hepatit Derg 2013; 19: 41-4.
  • 25. Çetinkol Y. Kars Devlet Hastanesi’ne Başvuran Hastalarda HBsAg, Anti-HCV ve Anti-HIV Seroprevalansı. Viral Hepatit Derg 2012; 18: 76-80.
  • 26. Turan H, Şerefhanoğlu K, Kanat-Ünler G, Arslan H. Seroprevalance of HBsAg and Anti-HCV and Their Correlation to Age and Gender in Blood Donors in the Province of Konya. Klimik Derg 2011; 24: 36-9.
  • 27. Karaaslan H, Yurdaydin C. Viral hepatitis at the Black Sea region: the problem of viral hepatitis in Turkey revisited. Turk J Gastroenterol 2009; 20: 1‐2.
  • 28. Aksu K, Kabasakal Y, Sayıner A, Keser G, Oksel F, Bilgiç A et al. Prevalences of hepatitis A, B, C and E viruses in Behçet's disease. Rheumatology 1999; 38: 1279-81.
  • 29. Erkek E, Ayaslioglu E, Erkek AB, Kurtipek GS, Bagci Y, Bagci Y. Response to vaccination against hepatitis B in patients with Behçet's disease. JGastroenterolHepatol2005; 20: 1508-11.
  • 30. Saco TV, Strauss AT, Ledford DK. Hepatitis B vaccine non-responders: possible mechanisms and solutions. AnnAllergy Asthma Immunol2018; 121: 320–27.
  • 31. Demir T. Kırşehir Bölgesindeki Kan Donörlerinin HBsAg, anti-HCV, anti-HIV 1/2 ve Sifiliz Seroprevalansı Yönünden Değerlendirilmesi. Viral Hepatit Derg 2010; 16: 111-6.
  • 32. Cicalini S, Gigli B, Palmieri F, Boumis E. AIDS and Behçet’s disease. Int J STD AIDS. 2004; 15: 139-40.

Behçet hastalığında HBsAg, Anti-HBs, Anti-HCV ve Anti-HIV seroprevalansı

Yıl 2021, Cilt 11, Sayı 5, 690 - 693, 17.09.2021
https://doi.org/10.16899/jcm.912691

Öz

Giriş: Behçet hastalığı bir Türk dermatoloğu olan Hulusi Behçet tarafından tanımlanmış; etyolojisi bilinmeyen, tekrarlayan aftöz ülserler, genital ülserler, üveit ve deri lezyonları ile karakterli inflamatuar hastalıktır. Çlışmamızda Behçet hastalarında HBV, HCV ve HIV seroprevalansını değerlendirmeyi amaçladık. Materyal ve Metod: Temmuz 2008 ile Temuuz 2020 tarihleri arasında dermatoloji polikliniğinde takip edilen Behçet hastalarının dosya bilgileri retrospektif olarak analiz edildi. Demografik verileri ile HBsAg, anti-HBs, anti-HCV, Anti-HIV sonuçları kaydedildi. Sonuçlar: 189'u kadın (52.6%) ve 170'i erkek (47.4%) olmak üzere yaş ortalamaları 37.7±12.3 olan 359 Behçet hastası değerlendirildi. 6 hastada (1.6%) HBsAg pozitif olduğu görülürken, 82 hastada (7.7%) Anti-Hbs antikorunun pozitif olduğu görüldü. Anti HIV antikorunun tüm hastalarda negatif olduğu görülürken, anti-HCV antikorunun ise sadece 1 hastada pozitif olduğu görüldü (0.2%) ve sonucun HCV-RNA ile kontrol edildiği ve negatif olduğu görüldü. Tartışma: Genel popülasyonla karşılaştırıldığında Behçet hastalarında seropozitiflik oranının yüksek olmadığı görüldü. Esasen immünite oranlarının düşük olduğu görüldü. Elde edilen sonuca göre immünsupresif tedavilerin arttığı günümüzde seroprevalans değerlendirmesinin Behçet hastalarında önemli olduğu düşünüldü. Ayrıca HBV göstergelerinin negatif olduğu hastalarda aşılama düşünülmelidir. Çalışma sonuçlarının genel olarak normal popülasyon ve diğer Behçet hastalığı ile ilgili seroprevalans çalışmalarından farklı olması ülkemizdeki ve bölgemizdeki farklılıklara bağlı olduğu düşünüldü.

Kaynakça

  • REFERENCES 1. Alibaz-Oner F, Direskeneli H. Behçet’s Disease: Clinical Features. In: Tüzün E. Kürtüncü M. (eds) Neuro-Behçet’s Disease. Springer, Cham 2021: 55-62.
  • 2. Sakane T, Mitsuhiro C, Suzuki N, Inaba G. Behçet's Disease. N Engl J Med 1999; 341: 1284-91.
  • 3. Idil A, Gürler A, Boyvat A, et al. The prevalence of Behçet’s disease above the age of 10 years. The results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. Ophthalmic Epidemiol. 2002; 9: 325–31.
  • 4. Alpsoy E, Donmez L, Onder M, et al. Clinical features and natural course of Behçet’s disease in 661 cases: a multicentre study. Br J Dermatol. 2007; 157: 901–6.
  • 5. Alpsoy E. Behçet’s disease: Treatment of mucocutaneous lesions. Clin Exp Rheumatol. 2005; 23: 532-9.
  • 6. EASL clinical practice guidelines. Management of chronic hepatitis B virusinfection. J Hepato 2017; l57: 167-85.
  • 7. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's diseas-An update Seminars in Arthritis and Rheumatism 2001; 30: 299-312.
  • 8. Law MF, Ho R, Cheung CK, Tam LHP, Ma K, So KCY et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol 2016; 22: 6484-500.
  • 9. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25: 864-71.
  • 10. Weinbaum CM, Williams I, Mast EE, Wang Sa, Finelli L, Wasley A et al. Recommendations for identification and public health management of persons with chronic hepatitis B virusinfection. MMWR Recomm Rep 2008; 57: 1-20
  • 11. Farajzadeh S, Shakibi MR, Darvish Moghaddam S, Rahnama Z. Behçet disease: clinical spectrum and association with hepatitis B and C viruses. Eastern Mediterranean Health J 2005; 11: 68-72.
  • 12. Etem AA, Etem EÖ, Doğan GT, Yıldırmak ST, Öz I. Seroprevalence of Hepatitis B, C Virus and HIV in Behçet’s Disease Living in Usak Region. J Clin Anal Med 2013; 4: 96-8.
  • 13. Munke H, Stockmann F, Ramadori G. Possible association between Behçet’s syndrome and chronic hepatitis C virus infection. New EngJ Med 1995; 332: 400–1.
  • 14. Hamuryudan V, Sonsuz A, Yurdakul S. More on hepatitis C virus and Behçet’s syndrome. New EngJ Med 1995; 333: 322–3.
  • 15. Ilter N, Şenol E, Gürer MA, Öztaş MO. Behçet’s disease and HCV infection. Int J Dermatol 2000; 39: 396–7.
  • 16. Vega LE, Espinoza LR. Vasculitides in HIV Infection. CurrRheumatolRep2020; 22: 60.
  • 17. Zhang X, Li H, Li T, Zhang F, Han Y. Distinctive rheumatic manifestations in 98 patients with human immunodeficiency virus infection in China. J Rheumatol 2007; 34: 1760–4.
  • 18. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011; 90: 359-71.
  • 19. Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.Gastroenterology 2017;152: 1297–309.
  • 20. Karadağ Ö, Kaşifoğlu T, Özer B, et al. Romatolojik hastalarda biyolojik ilaç kullanımı öncesi (viral) hepatit tarama kılavuzu. RAED Derg2015; 7: 28-32.
  • 21. Asan A, Akbulut A, Sacar S, Turgut H. Tunceli Devlet Hastanesi’ne başvuran kişilerde HBsAg ve Anti-HCV seroprevalansının değerlendirilmesi. Viral Hepatit Derg 2011; 17: 52-6.
  • 22. Tunç N, Eraydın H, Çetinkaya E, Oduncu MK, Toy Ş. Siirt Devlet Hastanesi’ne Başvuran Hastalarda HBsAg, Anti-HBs, Anti- HCV ve Anti-HIV Seroprevalansı. Viral Hepatit Derg. 2011; 17: 7-11.
  • 23. Demirpençe Ö, Tezcan SI, Değirmen E, Mert D, Gümüş A, Çelen MK. Batman Devlet Hastanesi’ne başvuran kişilerde Hepatit ve HIV Serolojisinin Sonuçları. Viral Hepatit Derg2012; 18: 6-10.
  • 24. İnci A, Okay M, Güven D. Artvin Devlet Hastanesi’ne Başvuran Hastalarda HBsAg, Anti-HBs, Anti-HCV ve Anti-HIV Seroprevalansı. Viral Hepatit Derg 2013; 19: 41-4.
  • 25. Çetinkol Y. Kars Devlet Hastanesi’ne Başvuran Hastalarda HBsAg, Anti-HCV ve Anti-HIV Seroprevalansı. Viral Hepatit Derg 2012; 18: 76-80.
  • 26. Turan H, Şerefhanoğlu K, Kanat-Ünler G, Arslan H. Seroprevalance of HBsAg and Anti-HCV and Their Correlation to Age and Gender in Blood Donors in the Province of Konya. Klimik Derg 2011; 24: 36-9.
  • 27. Karaaslan H, Yurdaydin C. Viral hepatitis at the Black Sea region: the problem of viral hepatitis in Turkey revisited. Turk J Gastroenterol 2009; 20: 1‐2.
  • 28. Aksu K, Kabasakal Y, Sayıner A, Keser G, Oksel F, Bilgiç A et al. Prevalences of hepatitis A, B, C and E viruses in Behçet's disease. Rheumatology 1999; 38: 1279-81.
  • 29. Erkek E, Ayaslioglu E, Erkek AB, Kurtipek GS, Bagci Y, Bagci Y. Response to vaccination against hepatitis B in patients with Behçet's disease. JGastroenterolHepatol2005; 20: 1508-11.
  • 30. Saco TV, Strauss AT, Ledford DK. Hepatitis B vaccine non-responders: possible mechanisms and solutions. AnnAllergy Asthma Immunol2018; 121: 320–27.
  • 31. Demir T. Kırşehir Bölgesindeki Kan Donörlerinin HBsAg, anti-HCV, anti-HIV 1/2 ve Sifiliz Seroprevalansı Yönünden Değerlendirilmesi. Viral Hepatit Derg 2010; 16: 111-6.
  • 32. Cicalini S, Gigli B, Palmieri F, Boumis E. AIDS and Behçet’s disease. Int J STD AIDS. 2004; 15: 139-40.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Bilimleri ve Hizmetleri
Bölüm Orjinal Araştırma
Yazarlar

Esma EROĞLU
Konya Meram Devlet Hastanesi
0000-0002-0181-6023
Türkiye


Cahit YAVUZ (Sorumlu Yazar)
Konya Şehir Hastanesi
0000-0003-4675-8127
Türkiye

Yayımlanma Tarihi 17 Eylül 2021
Kabul Tarihi 25 Haziran 2021
Yayınlandığı Sayı Yıl 2021, Cilt 11, Sayı 5

Kaynak Göster

AMA Eroğlu E. , Yavuz C. Seroprevalence of HBsAg, Anti-HBs, Anti-HCV and Anti-HIV in Behçet’s Disease. J Contemp Med. 2021; 11(5): 690-693.